VIGL Logo

Vigil Neuroscience, Inc. (VIGL) 

NASDAQ$1.98-0.04 (-1.98%)
Market Cap
$82.58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
333 of 924
Rank in Industry
194 of 527

VIGL Insider Trading Activity

VIGL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$48,9704100
Sells
$000

Related Transactions

Magovcevic-Liebisch IvanaPresident and CEO3$28,4500$0$28,450
Budd Haeberlein Samantha L.director1$20,5200$0$20,520

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral …

Insider Activity of Vigil Neuroscience, Inc.

Over the last 12 months, insiders at Vigil Neuroscience, Inc. have bought $48,970 and sold $0 worth of Vigil Neuroscience, Inc. stock.

On average, over the past 5 years, insiders at Vigil Neuroscience, Inc. have bought $17.69M and sold $4,200 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Magovcevic-Liebisch Ivana (President and CEO) — $28,450. Budd Haeberlein Samantha L. (director) — $20,520.

The last purchase of 5,000 shares for transaction amount of $8,400 was made by Magovcevic-Liebisch Ivana (President and CEO) on 2024‑12‑19.

List of Insider Buy and Sell Transactions, Vigil Neuroscience, Inc.

2024-12-19PurchaseMagovcevic-Liebisch IvanaPresident and CEO
5,000
0.0123%
$1.68$8,400+38.55%
2024-12-19PurchaseBudd Haeberlein Samantha L.director
12,000
0.0301%
$1.71$20,520+38.55%
2024-12-18PurchaseMagovcevic-Liebisch IvanaPresident and CEO
5,000
0.0124%
$1.67$8,350+36.97%
2024-12-05PurchaseMagovcevic-Liebisch IvanaPresident and CEO
5,000
0.0125%
$2.34$11,700-3.46%
2023-11-20PurchaseMagovcevic-Liebisch IvanaPresident and CEO
4,000
0.0114%
$3.75$15,000-6.85%
2022-11-18SalePapapetropoulos SpyrosChief Medical Officer
300
0.001%
$14.00$4,200-27.54%
2022-05-16PurchaseThorp Clay
14,893
0.0551%
$2.97$44,189+235.79%
2022-05-05PurchaseThackaberry EvanSVP, Head of Early Development
1,500
0.0064%
$4.00$6,000+185.03%
2022-05-03PurchaseZiolkowski Jennifer LynnChief Financial Officer
4,000
0.0149%
$3.77$15,098+163.16%
2022-05-03PurchaseVerni ChristopherGeneral Counsel
4,000
0.0148%
$3.77$15,074+163.16%
2022-05-03PurchasePapapetropoulos SpyrosChief Medical Officer
4,000
0.0134%
$3.40$13,591+163.16%
2022-05-02PurchaseMagovcevic-Liebisch IvanaPresident and CEO
4,000
0.0141%
$3.61$14,439+160.99%
2022-03-28PurchaseThorp Clay
3,000
0.0114%
$7.20$21,604+25.92%
2022-01-11PurchaseVitorovic Stefandirector
1.68M
7.4164%
$14.00$23.45M-24.96%
2022-01-11PurchaseVida Ventures GP III, L.L.C.10 percent owner
1.68M
7.4164%
$14.00$23.45M-24.96%
2022-01-11PurchaseBooth Brucedirector
535,000
2.3688%
$14.00$7.49M-24.96%
2022-01-11PurchaseAtlas Venture Fund XII, L.P.10 percent owner
535,000
2.3688%
$14.00$7.49M-24.96%
2022-01-11PurchaseThorp Claydirector
265,000
1.1733%
$14.00$3.71M-24.96%
2022-01-11PurchaseNorthpond Ventures GP, LLC10 percent owner
355,000
1.5718%
$14.00$4.97M-24.96%
Total: 19
*Gray background shows transactions not older than one year

Insider Historical Profitability

67.19%
Magovcevic-Liebisch IvanaPresident and CEO
222687
0.5447%
$449,827.7450+77.07%
Budd Haeberlein Samantha L.director
12000
0.0294%
$24,240.0010
Vitorovic Stefandirector
5004393
12.2418%
$10.11M10<0.0001%
Vida Ventures GP III, L.L.C.10 percent owner
5004393
12.2418%
$10.11M10<0.0001%
Booth Brucedirector
4808896
11.7636%
$9.71M10<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$4,919,189
138
5.22%
$95.3M
$49,091,668
110
13.11%
$83.06M
$155,580,641
77
-24.21%
$86.51M
$4,898,715
46
40.74%
$73.28M
$329,102,560
42
30.96%
$73.82M

VIGL Institutional Investors: Active Positions

Increased Positions30+51.72%3M+12.36%
Decreased Positions23-39.66%5M-16.14%
New Positions11New2MNew
Sold Out Positions12Sold Out3MSold Out
Total Postitions65+12.07%27M-3.78%

VIGL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Atlas Venture Life Science Advisors, Llc$11,790.0012.42%5.84M00%2024-12-31
Northpond Ventures, Llc$8,513.008.97%4.21M00%2024-09-30
Siren, L.L.C.$4,022.004.24%1.99M00%2024-12-31
Bvf Inc/Il$3,664.003.86%1.81M00%2024-12-31
Citadel Advisors Llc$3,045.003.21%1.51M+64,724+4.49%2024-12-31
Sphera Funds Management Ltd.$3,035.003.2%1.5M-145,175-8.81%2024-12-31
683 Capital Management, Llc$2,828.002.98%1.4M+180,420+14.79%2024-12-31
Vanguard Group Inc$1,970.002.08%975,473+70,742+7.82%2024-12-31
Ensign Peak Advisors, Inc$1,420.001.5%703,116+97,580+16.11%2024-12-31
Pivotal Bioventure Partners Investment Advisor Llc$1,132.001.19%560,59500%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.